Pneumococcal vaccine (PCV13)

The pneumococcal vaccine (PCV13) protects against 13 types of Streptococcus pneumoniae bacteria that can cause serious infections like pneumonia and meningitis, making it crucial for those at higher risk.

Studies have found that PCV13 is safe and effective in both adults over 50 years old and infants. In older adults who had previously received pneumococcal vaccines, the vaccine was well-tolerated with no significant safety concerns. For infants, a four-dose series of a similar but more extensive version (20-valent) showed strong immunogenicity without notable side effects.

This vaccine is particularly important for individuals over 65 and those with compromised immune systems, such as organ transplant recipients. It also plays a role in reducing the burden of pneumococcal disease in communities by preventing infections that can spread to others.

While studies support its safety and efficacy, more research could provide deeper insights into long-term effects and specific subgroup responses.

Sources

• A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6). (PMID:39082735)
• A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. (PMID:38535409)
• 13-valent pneumococcal conjugate vaccine (PCV13). (PMID:21941097)
• Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. (PMID:37669242)
• Pneumococcal immunity and PCV13 vaccine response in SOT-candidates and recipients. (PMID:34023135)
• A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination. (PMID:34839993)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._